Hypercapnia is not excluded by normoxia in neuromuscular disease patients: implications for oximetry.


Journal

ERJ open research
ISSN: 2312-0541
Titre abrégé: ERJ Open Res
Pays: England
ID NLM: 101671641

Informations de publication

Date de publication:
Jul 2024
Historique:
received: 23 11 2023
accepted: 16 02 2024
medline: 16 7 2024
pubmed: 16 7 2024
entrez: 16 7 2024
Statut: epublish

Résumé

Pulse oximetry is widely used in the assessment of chronic respiratory failure in neuromuscular disease (NMD) patients. Chronic respiratory failure is the major cause of morbidity and mortality, necessitating early diagnosis and intervention. Guidelines suggest that an arterial blood gas (ABG) measurement is indicated if oxygen saturation ( A single-centre retrospective audit of room-air ABGs in stable hypercapnic chronic respiratory failure patients from 1990 to 2020 was performed. Patients with parenchymal lung disease were excluded. Patients were grouped into three main categories: non-NMD, other NMD and motor neurone disease. 297 ABGs with hypercapnia from 180 patients with extrinsic restrictive lung disease were analysed. No patients with non-NMD, 54% of patients with other NMD and 36% of motor neurone disease patients demonstrated hypercapnia with normoxia (Chi-squared 61.33; p<0.001). The potential mechanism is proposed to be a difference in calculated respiratory quotient. If the alveolar-arterial gradient is assumed to be normal, the calculated respiratory quotient was significantly higher in motor neurone disease patients and other NMD patients compared with non-NMD patients (estimated marginal mean 0.99, 95% CI 0.94-1.03; 0.86 0.76-0.96; 0.73, 0.63-0.83, respectively; p<0.001) by mixed-model analysis. Hypercapnia is not excluded with normal oximetry in NMD patients and may be due to an elevated respiratory quotient. This has implications in the diagnosis and monitoring of respiratory insufficiency in NMD patients with oximetry alone.

Sections du résumé

Background UNASSIGNED
Pulse oximetry is widely used in the assessment of chronic respiratory failure in neuromuscular disease (NMD) patients. Chronic respiratory failure is the major cause of morbidity and mortality, necessitating early diagnosis and intervention. Guidelines suggest that an arterial blood gas (ABG) measurement is indicated if oxygen saturation (
Methods UNASSIGNED
A single-centre retrospective audit of room-air ABGs in stable hypercapnic chronic respiratory failure patients from 1990 to 2020 was performed. Patients with parenchymal lung disease were excluded. Patients were grouped into three main categories: non-NMD, other NMD and motor neurone disease.
Findings UNASSIGNED
297 ABGs with hypercapnia from 180 patients with extrinsic restrictive lung disease were analysed. No patients with non-NMD, 54% of patients with other NMD and 36% of motor neurone disease patients demonstrated hypercapnia with normoxia (Chi-squared 61.33; p<0.001). The potential mechanism is proposed to be a difference in calculated respiratory quotient. If the alveolar-arterial gradient is assumed to be normal, the calculated respiratory quotient was significantly higher in motor neurone disease patients and other NMD patients compared with non-NMD patients (estimated marginal mean 0.99, 95% CI 0.94-1.03; 0.86 0.76-0.96; 0.73, 0.63-0.83, respectively; p<0.001) by mixed-model analysis.
Interpretation UNASSIGNED
Hypercapnia is not excluded with normal oximetry in NMD patients and may be due to an elevated respiratory quotient. This has implications in the diagnosis and monitoring of respiratory insufficiency in NMD patients with oximetry alone.

Identifiants

pubmed: 39010884
doi: 10.1183/23120541.00927-2023
pii: 00927-2023
pmc: PMC11247367
pii:
doi:

Types de publication

Journal Article

Langues

eng

Informations de copyright

Copyright ©The authors 2024.

Déclaration de conflit d'intérêts

Conflict of interest: A. Piper has received honoraria from ResMed and Philips. The other authors have no conflicts of interest to declare.

Auteurs

Emma Gray (E)

Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, Australia.
Central Clinical Medical School, The University of Sydney, Camperdown, Australia.

Collette Menadue (C)

Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, Australia.

Amanda Piper (A)

Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, Australia.

Keith Wong (K)

Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, Australia.
Central Clinical Medical School, The University of Sydney, Camperdown, Australia.
Sleep Research Group, Woolcock Institute of Medical Research, Glebe, Australia.

Matthew Kiernan (M)

Central Clinical Medical School, The University of Sydney, Camperdown, Australia.
Department of Neurology, Royal Prince Alfred Hospital, Camperdown, Australia.
Brain and Mind Centre, The University of Sydney, Camperdown, Australia.

Brendon Yee (B)

Department of Respiratory and Sleep Medicine, Royal Prince Alfred Hospital, Camperdown, Australia.
Central Clinical Medical School, The University of Sydney, Camperdown, Australia.
Sleep Research Group, Woolcock Institute of Medical Research, Glebe, Australia.

Classifications MeSH